Altera Corporation - University Program April 2014 1. INTRODUCTION TO THE ALTERA QSYS TOOL For Quartus II 13.1 2Altera DE-series FPGA Boards For this tutorial we assume that the reader has access to an Altera DE-series board, such as the one shown in Figure1. Introduction to the Altera Qsys Tool. Smart Changes Program. Activity, dose of Qsymia, and other factors. SEE THE RESULTS. And the Qsymia Pregnancy Surveillance Program at 1-888-998-4887.

Will Qsymia Make You Thin? MED’s Apovian weighs in on just-approved weight-loss drug From BU Today By Rich Barlow The drug formerly known as Qnexa (now it’s Qsymia) has been approved by the Food and Drug Administration for weight loss.

Photo courtesy of Vivus. Anti-obesity wonder drug or a potentially dangerous substance begging for a recall?

That’s the debate sparked by federal approval of as a prescription drug for weight loss on July 17. After the most obvious question about Qsymia (it’s pronounced kyoo-sim-EE-uh), the second most obvious question is whether the drug works. Yes, with warnings about its use by certain patients, says Dr. Caroline Apovian, who heads. In fact, the School of Medicine associate professor has already prescribed a medication that’s a component of Qsymia for some of her patients. (Qsymia, formerly called Qnexa, includes two previously approved medications—one a stimulant that suppresses appetite, the other an anticonvulsant that controls seizures.) The (FDA) initially rejected the drug in 2010, but relented after reviewing new data presented by the manufacturer this year. In announcing its, the FDA said it had approved the drug for patients whose body mass index (BMI) is 30 or higher (i.e., they’re medically obese) or who have a BMI of at least 27 (medically overweight) plus at least one weight-related complication (e.g., adult diabetes, high blood pressure, high cholesterol, etc.) The FDA warned that certain people should not use Qsymia, including pregnant women.

The drug can cause birth defects if taken early in a pregnancy, even before a woman realizes she’s pregnant. (Women of childbearing age taking the drug are urged to use effective contraception.) The FDA warned that glaucoma and overactive thyroid patients, people taking antidepressants known as MAOIs, and those allergic either to Qsymia’s stimulant (phentermine) or anti-seizure medication (topiramate) should avoid the drug as well. Critics have noted that the stimulant in Qsymia was also a component in Fen-Phen, a diet drug craze in the 1990s that ultimately was discontinued after evidence linking it to heart valve problems. (The stimulant was not the cause of those problems, according to.) Bostonia asked Apovian to help address some of the questions surrounding Qsymia.

Caroline Apovian has been prescribing a component of Qsymia for her overweight patients. Photo by Frank Curran Bostonia: When did you begin prescribing it off label, and why? Apovian: I began off label as soon as I heard about Phase III [randomized, controlled multi-location] trial results a few years ago. Fifty percent of patients we see get prescribed anti-obesity medications in addition to diet and exercise, and we see 450 patients per month. The trial results of Qsymia produce the best weight loss we have seen since the era of Fen-Phen. What’s the significance of the FDA’s approval? In the arsenal of weight-loss weapons, how important is Qsymia?

It’s the second approval of an anti-obesity agent in 10 years and the best weight-loss agent. We need more drugs for obesity, as many drugs as there are for type 2 diabetes and hypertension. What warnings and contraindications has the FDA placed on Qsymia? Topiramate, one of Qsymia’s components, is teratogenic [can interfere with fetal development], and another component, phentermine, can increase heart rate and blood pressure. So women of childbearing age and people at risk of cardiovascular disease should watch out. What about critics who say weight-loss drugs generally don’t work well and can be dangerous, as in the case of Fen-Phen? We have evidence that a ten percent weight loss improves mortality and co-morbidities for obese patients, and doctors will evaluate the risk-versus-benefit of Qsymia, just like they do with any drug for other conditions. Serial rts cts protocol.